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Abstract
Background: Influenza is an acute respiratory disease that continues to cause global epidemics and pandemics in human with 
significant mortality and morbidity.
Objectives: This study was designed to identify the circulating influenza virus in Ibadan, Nigeria during the 2006/2007 season.
Methods: Throat swab samples were collected from patients presenting with acute respiratory tract infection at the Out-Patient 
Departments of  major hospitals in Ibadan over a period of  seven months from November 2006 to May 2007. Isolation of  in-
fluenza virus was performed using Madin-Darby Canine Kidney cell line and 10 days old chicken embryonated egg. Isolates was 
identified by haemagglutination and haemagglutination-inhibition assays using selected CDC Influenza reference antisera (A, B, 
subtype H1 and H3).
Results: Out of  128 patients tested, 21(16.4%) yielded positive for virus isolation. Identification of  the isolates showed that 
19(14.8%) were positive for influenza virus out of  which 11(8.6%) and 8(6.2%) were influenza A and B viruses respectively. 
Influenza A virus 6(4.7%) were subtype H1; 4(3.1%) were co-subtype H1 and H3; and 1(0.8%) was not inhibited by subtype H1 
and H3.
Conclusion: The circulation of  influenza virus A and B in this study is important to contributing knowledge and data to influ-
enza epidemiology and surveillance in Nigeria.     
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Influenza is an acute respiratory disease that continues to 
cause global epidemics and pandemics in humans with 
significant mortality and morbidity reported and docu-
mented every season1. Three distinct immunologic types 
of  influenza virus A, B and C have been classified2. The 
three major pandemics of  the twentieth century were 
caused by influenza virus type A, a member in the family 
Orthomyxoviridae. Influenza A viruses are classified into 
18 haemagglutinin (H1-H18) and 11 neuraminidase (N1-
N11) transmembrane proteins based on the antigenicity 
of  these glycoproteins3. Epidemics are usually caused by 
influenza virus type A or B. Type A virus can infect a va-
riety of  different host species including man, birds, pigs, 
horses and other animals. Influenza type B and C viruses 
only infect humans; however, influenza type C virus has 
been isolated in pigs4 and dogs5,6.
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The pandemics of  influenza are typically due to the emer-
gence of  ‘subtypes’ of  influenza A viruses as influenza B 
and C viruses have not been known to cause pandemic in 
the past7. When a significant “antigenic” shift in at least 
one of  the influenza A virus surface proteins haemag-
glutinin and neuraminidase occurs spontaneously, often 
there is no immunity to this new virus. This can lead to 
a pandemic if  the virus also achieved effective human 
to human transmission and replication causing serious 
illness. This can occur as it happened with Spanish flu 
caused by influenza virus of  the A/H1N1 subtype in 
19188,9. Evidence has shown that multiple lineage of  the 
same virus subtype can co-circulate, persist and re-assort 
in epidemiologically significant ways10. The tendency of  
influenza virus to undergo frequent and permanent an-
tigenic changes necessitates constant monitoring of  the 
global situation and annual adjustments in the compo-
sition of  influenza vaccines11. The World Health Orga-
nization (WHO) epidemiological models indicate that a 
pandemic would have the greatest impact on the poorest 
countries of  Asia and Africa as a result of  limited surveil-
lance11.
In 2001, the WHO African Region’s Integrated Disease 
Surveillance and Response strategy was implemented in 
Nigeria but the surveillance program captures inadequate 
data on influenza12. The public health programs in Nige-
ria have focused on avian influenza virus surveillance in 
animals as a result of  episodes of  zoonotic transmission 
of  avian influenza viruses in wild birds and poultry13,14. 
Human living in close proximity to domestic poultry 
and pigs increases the risk of  influenza to human health. 
Therefore, the Nigerian Federal Ministry of  Health ex-
tended influenza surveillance in 2008 in order to acquire 
epidemiologic and laboratory data on the influenza dis-
ease among humans and the circulating influenza virus 
types and subtypes15. Previous publications have reported 
serologic evidence of  influenza viruses circulating among 
humans in Nigeria13,15-21. There is however, urgent need 
for active surveillance and continuous monitoring of  cir-
culation of  influenza virus in humans for influenza pan-
demic preparedness and control in Nigeria and sub-Saha-
ra African countries.
Early warning of  the emergence of  a new strain requires 
active surveillance in which the general practitioners can 
play an important role. When surveillance is kept upon 
a community by records of  illness and repeated virolog-
ical tests, it is possible to detect sporadic instances of  
influenza virus infection. The detection and isolation of  
endemic and circulating influenza viruses will aid in the 
formulation of  effective vaccines and the development 
of  suitable method of  vaccination. Therefore, this study 
isolated and determined the circulating type and strains 
of  influenza virus from patients with acute respiratory 
tract infections (RTI) using haemagglutination (HA) and 
haemagglutination-inhibition (HI) assays for 2006/2007 
season in Ibadan, Nigeria.
Materials and method
Study population
The study was discussed and approved by the local Eth-
ics Committee. Throat swab samples were collected at 
the General Out-Patient Departments of  three regional 
hospitals in Ibadan, the South-Western part of  Nigeria 
(Figure 1) from November 2006 to May 2007 (dry to 
early onset of  raining season). All laboratory investiga-
tions were carried out at the Department of  Virology, 
College of  Medicine Ibadan. Acute RTI was defined as 
clinical presentation of  sudden onset of  fever (tempera-
ture ≥38.0°C), cough/sore throat, fatigue and sputum 
production, in any adult or child seeking care. Patients 
with acute RTI irrespective of  their age were eligible for 
sampling as long as the onset of  symptoms was within 
three days. Information on demographic characteristics, 
medical history and clinical signs such as muscle aches, 
chills, malaise, vomiting, abdominal pains, nasal stiffness, 
runny nose, headache, diarrhoea and neurological mani-
festations were recorded during patient’s enrolment.
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Informed consent was obtained from all patient or pa-
tient’s parents in the case of  children prior to sample col-
lection. Throat swabs were carefully collected from 128 
patients by trained clinicians using polyester fiber-tipped 
applicator to rub the posterior of  the tonsils, the soft pal-
ate and posterior wall of  the pharynx. The swabs were 
then carefully removed; the cotton tip of  swab stick was 
broken off  into a labelled screw-cap vial containing virus 
transport medium (Dulbecco’s modified eagle medium, 
2% Bovine serum albumin, 2% of  HEPES buffer and 
100 µg/ml of  penicillin/streptomycin). Samples were 
quickly transferred in a box containing ice packs to main-
tain cold-chain during the course of  transportation to the 
laboratory where they were inoculated immediately or 
stored under mechanical refrigeration at -80°C for lon-
ger than 24 h before analysis. However, prior to inocula-
tion, the throat swab samples in transport medium were 
treated with 100 µl of  antibiotics made of  penicillin and 
streptomycin in a laminar flow hood. This was left in a 
temperature of  4°C for 1 hour. The mixture was then fil-
tered by centrifugation in the cold at 1500 rpm to ensure 
separation of  debris from the fluid. The treated samples 
were then used for inoculation.
Virus isolation
Detection of  cytopathic effect (CPE) in cell line
Aliquots (100 µl) of  the throat swab samples were in-
oculated into the Madin-Darby Canine Kidney cell line 
(MDCK; WHO/CDC, USA) containing confluent cells 
previously seeded in tubes or microplates. Each sample 
was inoculated in duplicate and two tubes left not inoc-
ulated to serve as control. Inoculated culture tubes were 
incubated at 37°C and daily observation for CPE under 
inverted x10 microscope for 7-8 days was recorded ac-
cordingly. Cultures showing CPE were harvested when 
they had progressed to about 75% to 100% and subse-
quently passaged. Cultures with no visible CPE at the end 
of  day 7 were also retrieved for blind passage while sam-
ples not showing CPE after second passage were regard-
ed as negative. Cultures with CPE after second passage 
were further passed into MDCK in tissue culture flasks 
to increase the virus titer (50%). The CPE observed in-
clude cell granulation, swelling, cell fragmentation and 
dislodgement of  the cell monolayer.
Inoculation and harvesting of  embryonated egg
A small hole was drilled above the air space in the shell 
of  10 days old chicken embryonated eggs obtained from 
local hatchery. A 23-gauge needle attached to 1 ml sy-
ringe was inserted into the amniotic sac and 100 µl of  
the throat swab inoculum was injected into the amniotic 
cavity. An additional 200 µl inoculum was injected into 
the allantoic cavity. Two eggs were inoculated per sam-
ple. Two eggs were uninoculated to serve as control. The 
 
Figure 1: Location of the influenza study (indicated in black dot)  
in Ibadan, South-Western part of Nigeria 
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hole in the shell was thoroughly sealed with wax, labelled 
appropriately with date and incubated at 37°C for 3 days. 
Eggs were monitored daily by candling to determine the 
viability of  the eggs. Following incubation, eggs were 
chilled at 4°C for 4-24 hours to minimize bleeding during 
harvesting. The allantoic fluid was then harvested with 
a Pasteur pipette over the air sac and the amniotic fluid, 
with a short 23-guage needle attached to a 1 ml syringe. 
Samples with no haemagglutinating activity were harvest-
ed to passage into another set of  eggs. Two passages were 




Haemagglutination assay was performed on samples seri-
ally diluted in 2-fold steps in a microtiter plate using 0.5% 
washed chicken red blood cell (RBC) as indicator system 
including the controls (containing phosphate buffer saline 
and RBC). The plates were slightly agitated and then in-
cubated undisturbed at room temperature for 30 minutes 
after which the plates were observed for agglutinatina-
tion. Positive haemagglutinating viruses were further test-
ed quantitatively by calculating the 1HA and 4HA unit ti-
ters used to prepare the working virus dilution needed for 
haemagglutination-Inhibition (HI) assay. Those with high 
4HA (>22) titers were harvested and stored in aliquots at 
-80°C. The haemagglutination inhibition of  the unknown 
virus was identified using ready-to-use reference antisera 
and antigen: FR-1217- and FR-1218- mouse monoclonal 
antibody influenza types A and B (pool) respectively; FR-
54- and FR-572- monoclonal antibody influenza types A/
H1 and A/H3 respectively (WHO-Collaborating Centre 
for Influenza/CDC, Atlanta Georgia 30333, USA) pro-
vided in the WHO/CDC Influenza surveillance kit. Pos-
itive Influenza A and B viruses were identified according 
to WHO protocol. As different reference antisera were 
used, the ability of  the virus to bind to specific antise-
rum shows the type of  influenza virus either type A or B. 
The HI test is considered valid if  the positive reference 
antigen and its homologous antiserum demonstrate the 
expected HI titer and the back titration of  each antigen 
(unknown and positive control) is 4 HA units/25 µl.
Results
Fever, sputum production, cough, malaise, fatigue, runny 
nose and headache were common clinical manifestations 
observed in positive patients enrolled for the study. All 
patients with HA antibody to influenza virus tested by HI 
assay as described above presented with fever 19(100%). 
In this study, out of  62 male and 66 female patients test-
ed, 9(14.5%) and 10(15.2%) were positive for influenza 
virus infection respectively. Within the age group of  0–5 
years old, 14(12.8%) patients were tested positive for in-
fluenza virus while in the age groups 16-20 and 21-25 
years old; 1(100%) and 2(40%) patients were tested posi-
tive for influenza virus respectively (Table 1). 
In November 2006, out of  37 patients with acute re-
spiratory infection tested for influenza virus infection, 
7(18.9%) were positive for influenza virus infection (Ta-
ble 2). The number of  positive patients diminished over 
the month of  collection until May 2007, when it began to 
rise again.
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Table 1: Age distribution of tested and positive patients with influenza virus infection 
Age group (years) No of samples 
tested 
No (%) of positive 
0 - 5 109 14(12.8)  
                                           
6 -10 4 2(50)   
11 – 15 2 0   
16 - 20 1 1(100)   
21 - 25 5 2(40)   
26 – 30 4 0   
≥ 31 3 0   
Total 128 19(14.8)  
 
 
Table 2: Monthly distribution of tested and positive patients 
with influenza virus infection 
  
Month No of samples 
tested 
No (%) of positive 
November 2006 37 7(18.9)   
December 2006 35 4(11.4)   
January     2007 20 4(20)   
February   2007 14 3(21.4)   
March       2007 10 0   
April         2007 5 0   
May          2007 7 1(14.3)   
Total 128 19(14.8)  
 
In this study, out of  128 clinical samples collected from 
patients with respiratory infection, 21(16.4%) were posi-
tive for virus isolation in MDCK cell line and/or embryo-
nated egg cultures (Table S1). Out of  the 21 positive sam-
ples, 7(5.5%) and 18(14.1%) samples yielded positive in 
MDCK and embryonated egg cultures respectively while 
4(3.1%) samples were positive in both culturing systems. 
Identification of  the isolates with CDC reference antisera 
(Influenza type A, B, subtype H1 and H3) showed that 
19(14.8%) were positive for influenza virus out of  which 
11(8.6%) was identified as influenza A virus and 8(6.2%) 
as influenza B virus. Further analysis showed that for in-
fluenza A virus of  which 6(4.75%) were subtype H1 and 
4(3.1%) were co-subtype H1 and H3, 1(0.8%) was not 
inhibited by subtype H1 and H3 as identified by HI. Out 
of  the four samples positive in both culturing systems, 
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two were influenza type A/H1 and H3; one was influenza 
type B; and one was influenza type A (not subtype). Two 
of  the isolates that haemagglutinated chicken RBC could 
not be identified with the available antisera A and B (Ta-
ble S1). These isolates were sent to WHO collaborating 
Centre in Atlanta for further molecular investigation.
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Discussion
In this study, influenza A virus was the type most fre-
quently isolated and identified within the study popula-
tion in 2006/2007 season. Previous reports have shown 
that Influenza A is predominantly in circulation in Ni-
geria15-21 which corroborates with findings from other 
sub-Saharan African countries22,23. Influenza A virus was 
the most common circulating influenza virus type iden-
tified within Nigeria in 2009 pandemic20,21. Information 
on worldwide influenza surveillance data accessed from 
the WHO database (FluNet) was used to compare the 
influenza type that predominates in Nigeria with those in 
other sub-Saharan African countries for 2006/2007 sea-
son. Regrettably, most of  these countries including Ni-
geria had no data available for 2006/2007. In 2006, how-
ever, influenza virus A/H1, A/H3 and A (not subtyped) 
predominated in Senegal, Cameroun and South Africa 
respectively. Contrarily, influenza B virus predominated 
in Kenya. In 2007, influenza virus type A (not subtyped) 
predominated in Kenya and South Africa; type A/H3 
predominated in Cameroun; and type B predominated 
in Senegal24. Influenza surveillance in African countries 
is very limited, the seasonality and epidemiology of  the 
influenza viruses need to be fully understood though. 
Importantly, pre- and post-pandemic data extending over 
years is required to understand why influenza virus B is 
less detected compared to type A influenza viruses, most 
particularly, in Nigeria. We recognized that the results of  
this study are not a representative of  the entire popula-
tion of  Nigeria which may be a possible shortcoming. 
Nevertheless, to the best of  our knowledge, it is the first 
study to provide insight to the type of  human influenza 
virus circulating among patients presenting with respira-
tory infection in Nigeria in 2006/2007. In a study that 
was carried out at Olympic Village Polyclinic during the 
2002 Winter Olympiad in Salt Lake City, USA in February 
and March 2002, 188 patients were screened for influenza 
and influenza A was detected in 28(15%) and influenza 
B in 8(4%) patients25, showing predominance of  influen-
za A. According to26 Morbidity Mortality Weekly Report 
shows that influenza B is less common in circulation.
In this study, it was demonstrated that in patients pos-
itive to influenza virus infection, fever (100%) was fre-
quent and consistent which corroborate the report by27,28 
Centre for Disease Control reported that influenza virus 
infection is usually abrupt with symptoms of  malaise, ex-
treme fatigue, headache, cough rhinitis and sore throat. 
This is similar to our findings as the following symptoms 
were common; sputum production 18(94.7%). cough 
16(84.2%), malaise 14(73.7%), fatigue 14(73.7%), head-
ache 14(73.7%) and runny nose 14(73.7%). However, the 
number of  positive patients with sore throat 6(31.6%) 
was rather low. This was because most of  the patients 
sampled were children, within the age-group of  0–5 years 
and they were unable to describe the sensation of  sore 
throat not even the parents. This at the same time was not 
obvious to the clinicians and some researchers.
Influenza virus is notoriously known for its unique abil-
ity to cause recurrent epidemics and pandemics during 
which acute febrile respiratory illness occurs explosively 
in all age-groups. In this study, a significant higher num-
ber of  samples were collected from children in age group 
0–5 years. Children aged less than 2 years were among the 
groups that are at risk of  serious illness and death from 
influenza17. Although distribution of  influenza virus type 
based on age group is not shown in our data, out of  all 
19 patients tested positive to influenza; a high number 
14(12.8%) were detected in children of  age group 0–5 
years. It has been reported that children (5–17 years old) 
were most frequently infected with influenza virus20. 
This shows a high risk of  susceptibility of  children to the 
infection. This can be as a result of  immune immaturi-
ty in neonate. More so, young children can shed copious 
number of  virus in droplets by sneezing and coughing 
for longer days and can be infectious for over ten days29. 
Parent tends to show immediate attention by bringing 
their children to hospital immediately they show signs of  
illness. In our study, it was observed that adults usually 
regard flu-like symptoms as common cold, therefore not 
taking it serious to consult physicians until the condition 
becomes severe. At this period, they are often unsuitable 
for throat swab collection for virus isolation.
Genetic re-assortment can occur between two different 
subtypes of  influenza A viruses resulting into pandem-
ic30. Although, in this study, co-circulation of  influenza A 
subtypes H1 and H3 was observed, it would be inappro-
priate to draw conclusion about the possibility of  pan-
demic by influenza A virus subtype H1/H3 or emergence 
of  a new subtype of  influenza A virus on the basis of  our 
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data. Multiple lineages of  the same virus subtypes can 
co-circulate persistently and re-assort in an epidemiolog-
ically significant ways10. At present, H1 and H3 subtypes 
of  influenza A viruses are the predominant type causing 
epidemic infections in the human population29,31. In our 
study, it is plausible that the two isolates uninhibited by 
antisera (A and B) may be influenza C or another hae-
maglutinating virus such as measles or mumps as they 
showed no CPE on MDCK. A limitation to this study, 
however, is the need for molecular investigation in order 
to identify unknown isolates, confirm the possibility of  
dual infection (H1 and H3), re-assortment and N sub-
types.
Nigeria lies within the tropical zone of  West Africa re-
gion. There are basically two distinct seasons in Nigeria 
namely the rainy/wet (April–October) and dry/harmat-
tan (November–March) seasons influenced by maritime 
tropical air from the Atlantic Ocean and continental trop-
ical air of  the Sahara Desert respectively. Rainfall is the 
key climatic variable; there is a marked alternation of  the 
two seasons in most areas though32. The seasonality of  
influenza viruses in the tropics has been associated with 
the rainy season33,34,35. In Nigeria, however, studies have 
suggested that influenza virus infection is more associat-
ed with the dry (harmattan) period15,36. In this study, the 
outbreak of  influenza virus infection coincided with the 
onset of  harmattan season (November to February). At 
the cessation of  harmattan precisely March and April, pa-
tients tested were negative to influenza. This suggests that 
influenza virus spreads and thrives well in harmattan, giv-
ing a favourable condition forits transmission. This may 
explain why the number of  positive patients was high be-
tween November 2006 and January 2007 (Table 2).
Conclusion 
This study established the circulation of  influenza A (H1 
and H3) and B viruses within the study population in 
Ibadan, Nigeria. The rise of  influenza B virus co-circu-
lation may eventually displace and replace the dominant 
influenza A virus in Nigeria. Influenza virus contributes 
to the occurrence of  mild cases of  respiratory infection 
most especially in children. Although most cases of  RTI 
were not positive for influenza, other respiratory diseases 
should be considered in influenza surveillance. The fact 
that mortality impact of  influenza epidemics and pan-
demics is devastating; this study affirmed the importance 
and need for influenza surveillance within sub-Saharan 
Africa. Data from this study strengthens influenza sur-
veillance system which can be integrated into the pub-
lic health programs in Nigeria and sub-Sahara African 
countries. Regular and active continuous monitoring and 
surveillance by isolation, characterization and molecular 
sequencing through laboratory investigation is thus nec-
essary to further enhance diagnostic and epidemiological 
data on influenza in Nigeria.
Supplementary material
Supplement data associated with this article is provided as 
(Supplemental) Table S1.
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